Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3',5'-Difluorobiphenyl-4-carboxylic acid is a synthetic small molecule belonging to the biphenyl carboxylic acids class. It features two fluorine atoms at the 3' and 5' positions of one phenyl ring and a carboxylic acid group at the para position of the other ring. This compound has been studied as an experimental agent for its ability to bind and stabilize transthyretin (TTR), thereby inhibiting amyloid fibril formation associated with TTR amyloidosis. Biophysical studies indicate that it acts by kinetically stabilizing TTR tetramers, raising the kinetic barrier for tetramer dissociation—a key step in amyloidogenesis[2][9]. Its primary use is in research settings; it has not been approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3',5'-difluorobiphenyl-4-carboxylic acid.